Centocor takes up UK Medical Research Council's respiratory immunotherapy
This article was originally published in Scrip
Executive Summary
The UK Medical Research Counciland MRC Technology have licensed rights to an immunotherapy with potential in respiratory disease to CentocorOrtho Biotech (Johnson & Johnson). Centocor has exclusively licensed patents to the technology and will pay development milestone and royalties on any net sales that may result.